AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00505752 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant human chorionic gonadotropin (r-hCG)
Description: Recombinant human chorionic gonadotropin (r-hCG) will be administered as a single dose of 250 mcg subcutaneously, when follicular response is adequate (that is, at least 1 follicle with a diameter of greater than or equal to \[>=\] 18 millimeter \[mm\], two or more additional follicles with a diameter of >= 16 mm, and Estradiol \[E2\] levels will approximately 150 picogram per milliliter \[pg/mL\] per mature follicle).
Study NCT02928380 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental Denture Adhesive
Description: Participants received a single application of test denture adhesive with a Flat Ribbon Nozzle as 3 Continuous strips those were applied to upper denture and one continuous strip that was applied to the lower denture which were placed in the mouth.
Study NCT02928380 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Reference (Marketed) Denture Adhesive
Description: Participants received a single application of marketed denture adhesive with a flat ribbon nozzle as a 3 dabs those were applied to upper denture and 2 dabs those were applied to lower denture, which were placed in the mouth.
Study NCT00292747 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Drotaverine
Study NCT00292747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drotaverine
Study NCT00292747 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Drotaverine Placebo
Study NCT00292747 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Study NCT00292747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen Placebo
Study NCT02174783 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Patient will be provided with basic nutrition educational materials that outline principles of a healthy diet, including: moderation, portion control, increased intakes of fruits, vegetables and whole grains and reduced intakes of saturated fat, salt and sugar. Brief education will be provided by the hepatologist without dietitian referral.
Study NCT02174783 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Description: Patient will receive verbal diet instruction from the dietitian or from the hepatologist who has received instruction from the dietitian on following the Mediterranean diet.
Study NCT02174783 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Protein-Sparing Modified Fast (PSMF)
Description: Patient will be referred to the dietitian for an appointment to discuss the PSMF plan.~Protein needs of 1.5 grams/kilogram will be calculated based on patient's actual body weight.~Patient will receive verbal instruction from the dietitian, as well as printed materials for reference at home. Dietitian will provide a list of allowed and prohibited foods as per Cleveland Clinic's PSMF diet standards.
Study NCT00502528 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Peri-interventional
Study NCT00502528 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BQ-123
Description: Peri-interventional
Study NCT03943446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-018
Description: TAK-018 immediate-release tablets.
Study NCT03943446 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TAK-018 Placebo
Description: TAK-018 placebo-matching tablets.
Study NCT03055572 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Olfactory Training with Essential Oils
Description: Participants will be instructed to sniff one of four provided odors for approximately 10 seconds followed by a 10 second break before repeating with each successive odor for a total of 5 minutes. Essential oils will be used for the odors. The intervention will be completed in the morning before breakfast and in the evening before bed. Participants will document compliance by completing a log of olfactory training sessions.
Study NCT00653055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabergoline
Description: Tablets, 0.5 mg (2 x 0.5 mg dose),fasting
Study NCT00653055 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dostinex
Description: Tablets, 0.5 mg (2 x 0.5 mg dose), fasting
Study NCT03055572 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Olfactory Training with Pure Fragrance Oils
Description: Participants will be instructed to sniff one of four provided odors for approximately 10 seconds followed by a 10 second break before repeating with each successive odor for a total of 5 minutes. Pure fragrance oils will be used for the odors. The intervention will be completed in the morning before breakfast and in the evening before bed. Participants will document compliance by completing a log of olfactory training sessions.
Study NCT03439111 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Standardized Lycium chinense Fruit Extract (LCF) capsules
Description: All dried water extracts and capsules of the Standardized Lycium chinense Fruit Extract (LCF) and Standardized Lycium chinense Fruit Extract (LCF)-matched placebo capsules used in the present study were manufactured and provided by the BIOMIX Company (Ilsan City, Korea).
Study NCT03439111 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Standardized Lycium chinense Fruit Extract (LCF) capsules
Description: All dried water extracts and capsules of the Standardized Lycium chinense Fruit Extract (LCF) and Standardized Lycium chinense Fruit Extract (LCF)-matched placebo capsules used in the present study were manufactured and provided by the BIOMIX Company (Ilsan City, Korea).
Study NCT03694054 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Care coordination tool
Description: Participants will be asked to enroll in the care coordination tool, a health information technology solution that integrates cross-sector data to enhance communication and improve quality of care and performance outcomes. Patients will also be asked to provide consent to allow the study team to access additional health information via the electronic health record.
Study NCT01755312 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medication reminder
Description: Medication reminder
Study NCT00873288 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care mailing intervention
Description: routine colposcopy reminder letter
Study NCT03719807 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation protocol
Description: A physiotherapy rehabilitation protocol - comprising of pragmatic exercises.
Study NCT03719807 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: No routine outpatient physiotherapy. Normal inpatient physiotherapy to match intervention group.
Study NCT00873288 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CIS support mailing intervention
Description: Mailed reminder plus provider recommendation to call CIS and sample questions to ask
Study NCT02980692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SUNPG1623 I
Description: injection
Study NCT02980692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SUNPG1623 II
Description: injection
Study NCT02980692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SUNPG1623 III
Description: injection
Study NCT02980692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SUNPG1623 IV
Description: injection
Study NCT02980692 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: injection
Study NCT02980692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLACEBO
Description: injection
Study NCT03479216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Precedex
Description: 10 ml of Bupivacaine ve 50mcg Dexmetedomidin mixture will be injected intraarticularly at the end of the surgery.
Study NCT03479216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate
Description: 10 ml of Bupivacaine ve magnesium sulfate mixture will be injected intraarticularly at the end of the surgery.
Study NCT02765503 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: External beam radiotherapy
Description: External beam radiotherapy using megavoltage radiotherapy with radical intent.
Study NCT02765503 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External beam radiotherapy
Description: External beam radiotherapy using megavoltage radiotherapy with radical intent.
Study NCT04019795 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: REVIAN 101
Description: The REVIAN System includes a Cap configured for portable use with rechargeable battery and adapter with active LEDs using modulated light therapy (MLT trademark). Daily 10-minute treatments are done in the home over the course of 26 weeks. Intervention adherence will be assessed via firmware in the Cap and monitored by the clinical sites.~REVIAN 101 delivers 625 nm and 660 nm wavelengths of red light.
Study NCT04019795 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: REVIAN 102
Description: The REVIAN System includes a Cap configured for portable use with rechargeable battery and adapter with active LEDs using modulated light therapy (MLT trademark). Daily 10-minute treatments are done in the home over the course of 26 weeks. Intervention adherence will be assessed via firmware in the Cap and monitored by the clinical sites.~REVIAN 102 delivers 425 nm wavelength of blue light.
Study NCT04019795 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: REVIAN 103
Description: The REVIAN System includes a Cap configured for portable use with rechargeable battery and adapter with active LEDs using modulated light therapy (MLT trademark). Daily 10-minute treatments are done in the home over the course of 26 weeks. Intervention adherence will be assessed via firmware in the Cap and monitored by the clinical sites.~REVIAN 103 delivers 425 nm wavelength of blue light and 625 nm and 660 nm wavelengths of red light.
Study NCT04019795 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: REVIAN 100
Description: The REVIAN System includes a Cap configured for portable use with rechargeable battery and adapter with active LEDs using modulated light therapy (MLT trademark). Daily 10-minute treatments are done in the home over the course of 26 weeks. Intervention adherence will be assessed via firmware in the Cap and monitored by the clinical sites.~REVIAN 100 contains LEDs that are not powered for light therapy
Study NCT03649334 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: ketamine-ketorolac
Description: The patient will receive ketamine 0.5mg.kg-1 + ketorolac 1mk.kg-1 in 2 ml syringe intramuscularly.
Study NCT03649334 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: fentanyl- ketorolac
Description: The patient will receive fentanyl 1.5ug.kg-1 + ketorolac 1 mg.kg-1 in 2ml syringe intramuscularly
Study NCT02521298 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength Training
Study NCT01946360 — intervention group
Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: Methacetin Breath Test in ACLF and ALF patients
Description: Methacetin Breath Test will be done on Day 0,7,14,28 in Acute on Chronic Liver Failure (ACLF)and on day 0,1,3,7 in Acute Liver failure (ALF).
Study NCT03792087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SmofKabiven Peripheral
Description: Total Parenteral Nutrition
Study NCT02521298 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Strength Training
Study NCT02521298 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study NCT02521298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cortico-Steroid Injection. Depomedrol 40mg/1ml.
Study NCT02521298 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dry Needling
Study NCT02169804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androxal 25 mg
Study NCT04169113 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group 1 - Opiate Tablets post Hip Arthroscopy
Description: Will be prescribed 60 opiate tablets in addition to other routine post-operative pain medication regimens.
Study NCT04169113 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group 2 - Opiate Tablets post Hip Arthroscopy
Description: Will be prescribed 30 opiate tablets in addition to other routine post-operative pain medication regimens.
Study NCT03823040 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxiconazole Nitrate Cream 1%
Description: Tinox® group was treated with oxiconazole nitrate cream 1 % . Treatment was performed by rubbing the cream twice daily for two/ four weeks according to different types of tinea.
Study NCT03823040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxiconazole nitrate SLNs loaded gel.
Description: Oxiconazole nitrate SLNs loaded gel group was treated with oxiconazole nitrate SLNs loaded gel.Treatment was performed by rubbing the gel twice daily for two/ four weeks according to different types of tinea.
Study NCT03792087 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hospital compounded emulsion
Description: Total Parenteral Nutrition
Study NCT00952536 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Daily Juice Plus+ with vegetable & fruit & berry capsule
Description: Daily Juice Plus+ with 2 vegetable \& 2 fruit \& 2 berry capsule
Study NCT00952536 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Daily Juice Plus+ vegetable & fruit & placebo capsule
Description: Daily Juice Plus+ with vegetable \& fruit \& placebo capsule
Study NCT00003476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antineoplaston therapy (Atengenal + Astugenal)
Description: Children with a primary malignant brain tumor will receive Antineoplaston therapy (Atengenal + Astugenal).
Study NCT05893667 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Inflammatory markers
Description: analysis of inflammatory scores
Study NCT00952536 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo in the form of 6 capsules
Description: Daily Placebo in the form of 6 capsules (control group)
Study NCT04312269 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Targeted Memory Reactivation (TMR)
Description: Targeted memory reactivation (TMR) refers to the process of playing audio cues associated with specific learned material quietly during sleep in order to strengthen consolidation of specific memories during sleep.
Study NCT04312269 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Targeted Memory Reactivation (TMR)
Description: Targeted memory reactivation (TMR) refers to the process of playing audio cues associated with specific learned material quietly during sleep in order to strengthen consolidation of specific memories during sleep.
Study NCT03710720 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TIPS app
Description: Psycho-educational electronic application
Study NCT03710720 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Trauma Focused-Cognitive Behavioral Therapy
Description: Effective form of trauma therapy for adolescents
Study NCT03710720 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trauma Focused-Cognitive Behavioral Therapy
Description: Effective form of trauma therapy for adolescents
Study NCT01731795 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone (20 mg/iv/daily/from Day 1 of randomization during 5 days, followed by 10 mg/iv/daily/ from Day 6 to 10 of randomization)
Study NCT02935192 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccine
Description: Seasonal trivalent split, inactivated influenza vaccine 15 mcg hemagglutinin antigen (HA) of each of A/H1N1; A/H3N2 and B strains; 0.5 mL by IM injection
Study NCT02935192 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Phosphate buffered saline, 0.5 mL by IM injection
Study NCT05353686 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects in the placebo arm will receive an oral tablet containing no active drug twice daily
Study NCT05353686 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: XEN-D0501
Description: Subjects in the XEN-D0501 arm will receive an oral tablet containing 4 mg/tablet of IMP twice daily
Study NCT01206517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asenapine 2.5 mg
Description: Asenapine tablet, sublingually (SL), 2.5 mg b.i.d. on Days 1-6 and one 2.5 mg tablet, SL, on Day 7.
Study NCT01206517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asenapine 5 mg
Description: Asenapine tablet, SL, 5 mg b.i.d. on Days 1-6 and one 5 mg tablet, SL, on Day 7.
Study NCT01206517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asenapine 10 mg
Description: Asenapine tablets, SL, in a rising dose schedule to 10 mg b.i.d. (with a single 10 mg dose on final day). For Cohorts 3b, 3c and 3d, rising dose schedule begins with asenapine 5 mg b.i.d. on Day 1 and dosing occurs through Day 8. For Cohort 3a, rising dose schedule begins with asenapine 2.5 mg b.i.d. on Day 1 and dosing occurs through Day 12.
Study NCT01775527 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: blood test
Study NCT02164526 — intervention group
Intervention type: OTHER
Intervention: Routine therapy
Description: Routine therapy
Study NCT01973868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib (Stivarga, BAY73-4506)
Study NCT00258401 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: dietary intervention
Description: At the onset of diarrhea symptoms, patients are instructed to eat a low-residue diet. Patients continue on this diet for 2-4 weeks.
Study NCT00258401 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: management of therapy complications
Description: Interviewed weekly for up to 6 weeks to monitor dietary intake, bowel symptoms, diarrhea events, FI-QOL, and changes in CTC scores.
Study NCT03453918 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: polyphenols
Description: After 6 hours of fasting, each patient will eat a complete meal course, containing 40 mg of iron, at two different days (wash-out period: 3 days between each meal).~During each meal, each patient will receive, two capsules containing polyphenols or two placebo capsules (cross-over methodology). The meal in which each patient will receive either polyphenol or placebo will be randomized.~The diet consists of :~* Starter: duck gizzard salad.~* Main course: black pudding and pasta.~* French cheese.~* Fruits: kiwi fruit.~This diet contain approximately 40 mg of iron, with low polyphenol intake. Patients will be asked to eat the whole gizzard and black pudding to ensure the highest iron intake.~At the end of the meal, blood samples will be collected at 0 minute, 30 minutes, 1 hour, 2 hours, 3 hours and 4 hours, to assess serum iron level, in order to measure the area under the curve of iron kinetic.
Study NCT01973868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab (ERBITUX)
Study NCT03453918 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: After 6 hours of fasting, each patient will eat a complete meal course, containing 40 mg of iron, at two different days (wash-out period: 3 days between each meal).~During each meal, each patient will receive, two capsules containing polyphenols or two placebo capsules (cross-over methodology). The meal in which each patient will receive either polyphenol or placebo will be randomized.~The diet consists of :~* Starter: duck gizzard salad.~* Main course: black pudding and pasta.~* French cheese.~* Fruits: kiwi fruit.~This diet contain approximately 40 mg of iron, with low polyphenol intake. Patients will be asked to eat the whole gizzard and black pudding to ensure the highest iron intake.~At the end of the meal, blood samples will be collected at 0 minute, 30 minutes, 1 hour, 2 hours, 3 hours and 4 hours, to assess serum iron level, in order to measure the area under the curve of iron kinetic.
Study NCT00661830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m2 body surface i.v. first cycle at day 1, 8, 15, 22, 29, 36, 43. Next cycles at day 1, 8, 15.
Study NCT00661830 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m2 body surface i.v. first cycle at day 1, 8, 15, 22, 29, 36, 43. Next cycles at day 1, 8, 15.
Study NCT00661830 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00661830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Sorafenib 400 mg bid orally continuously
Study NCT04152486 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.ZEBOV, MVA-BN-Filo vaccine
Description: Ad26.ZEBOV: a monovalent vaccine expressing the full-length glycoprotein (GP) from Ebola virus (EBOV) Mayinga. The vaccine is produced in the human cell line PER.C6®.~MVA-mBN226B: further referred to as Modified Vaccinia Ankara (MVA)-BN®-Filo. This is a multivalent vaccine expressing the EBOV GP, the Sudan virus (SUDV) GP, the Marburg virus (MARV) Musoke GP, and the Taï Forest virus (TAFV, formerly known as Côte d'Ivoire ebolavirus) nucleoprotein (NP). The EBOV GP expressed by MVA BN Filo has 100% homology with the one expressed by Ad26.ZEBOV.
Study NCT01370876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin will be administered as a 2-hour infusion first on Day 1, followed by 5-FU i.v. infusion for 48 hours (Day 1 and Day 2), repeated every 2 weeks, 4 weeks as a cycle.